Wall Street analysts forecast that Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) will post ($0.20) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Hepion Pharmaceuticals’ earnings. Hepion Pharmaceuticals posted earnings of ($0.97) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 79.4%. The business is scheduled to announce its next earnings report on Monday, July 5th.
According to Zacks, analysts expect that Hepion Pharmaceuticals will report full-year earnings of ($0.47) per share for the current financial year, with EPS estimates ranging from ($0.77) to ($0.26). For the next fiscal year, analysts forecast that the business will report earnings of ($0.49) per share, with EPS estimates ranging from ($0.77) to ($0.21). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Hepion Pharmaceuticals.
Separately, Zacks Investment Research lowered shares of Hepion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday.
In other Hepion Pharmaceuticals news, CEO Robert T. Foster purchased 20,000 shares of the stock in a transaction on Thursday, February 18th. The stock was acquired at an average cost of $2.00 per share, with a total value of $40,000.00. Insiders own 0.10% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. ExodusPoint Capital Management LP purchased a new position in shares of Hepion Pharmaceuticals during the third quarter valued at about $36,000. Allen Capital Group LLC bought a new position in shares of Hepion Pharmaceuticals in the fourth quarter worth approximately $52,000. Prospera Financial Services Inc bought a new position in shares of Hepion Pharmaceuticals in the fourth quarter worth approximately $86,000. Bank of New York Mellon Corp bought a new position in shares of Hepion Pharmaceuticals in the fourth quarter worth approximately $90,000. Finally, Northern Trust Corp bought a new position in shares of Hepion Pharmaceuticals in the fourth quarter worth approximately $139,000. Institutional investors own 2.97% of the company’s stock.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B.
Further Reading: What is a death cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hepion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hepion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.